Paul A. Tambyah
Expertise in
8
conditions

Paul A. Tambyah

1E Kent Ridge Rd, 
Singapore, SG 
Expertise in
8
conditions
1E Kent Ridge Rd, 
Singapore, SG 

Overview

Paul Tambyah practices practicing medicine in Singapore, Singapore.

Mr. Tambyah is highly rated in 8 conditions, according to our data. His clinical expertise encompasses COVID-19, Severe Acute Respiratory Syndrome (SARS), Pneumonia, Urinary Tract Infection (UTI), and Thrombectomy.

He is actively involved in clinical research, co-authoring 269 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

1E Kent Ridge Rd, Singapore, 119228, Singapore
Other Locations
Singapore. 5 Lower Kent Ridge Rd, Singapore, 119074, Singapore
1 Jurong East Street 21, Singapore, 609606, Singapore

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.
Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.
Enrollment Status: Terminated
Publish Date: November 27, 2017
Intervention Type: Drug
Study Phase: Phase 4

269 Total Publications

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).
Journal: Critical care medicine
Published: May 08, 2026

Frequently Asked Questions about Paul A. Tambyah

Is Paul A. Tambyah a top-rated expert for COVID-19?

MediFind is an objective health platform that identifies experts based on real-world data. Paul A. Tambyah is classified as an Distinguished expert for COVID-19, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Paul A. Tambyah participate in research or clinical trials?

Yes. Paul A. Tambyah has published 269 articles and abstracts on conditions like COVID-19. You can view a list of Paul A. Tambyah's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tambyah's expertise for a condition
ConditionClose
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile